MetaCap

Aardvark Therapeutics (AARD) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TransCode Therapeutics (RNAZ) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 86.6% versus a loss of 90.2%. Aardvark Therapeutics is the larger company by market cap ($20.2 million vs $20.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%RNAZ-86.57%
+77%-11%-98%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%RNAZ-99.60%
+28%-39%-106%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus RNAZ key metrics
MetricAARDRNAZ
Share price$0.9226$1.16
Market cap$20.20M$20.07M
1-day change-7.74%-10.77%
YTD return-92.97%-83.02%
1-year return-90.15%-86.57%
5-year return—-100.00%
EPS (TTM)$-3.33$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-57.59M$-34.66M
52-week high$16.60$12.60
52-week low$0.90$1.01
Distance from 52-week high-94.44%-90.79%
Analyst consensusbuy—
Avg. price target upside+1104.21%—
Average volume643.53K52.03K
Shares outstanding21.89M17.30M
Employees2812
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

AARD vs RNAZ FAQ

Which is bigger, Aardvark Therapeutics or TransCode Therapeutics?

Aardvark Therapeutics (AARD) is larger, with a market capitalization of $20.20M compared with $20.07M for TransCode Therapeutics (RNAZ).

Which stock has performed better over the past year, AARD or RNAZ?

RNAZ returned -86.57% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons